Serum alkaline phosphatase in patients with multiple sclerosis

Area of Science:

• Biochemistry
• Immunology
• Neurology

Background:

• Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
• Intestinal alkaline phosphatase (serum type Pp2) is an enzyme with potential roles in immune regulation and gut health.
• Previous research has not extensively explored the relationship between serum Pp2 levels and MS pathogenesis.

Purpose of the Study:

• To investigate serum levels of intestinal alkaline phosphatase (serum type Pp2) in patients with multiple sclerosis.
• To compare Pp2 levels between MS patients and a healthy control group.
• To determine if blood group or secretor status influences Pp2 levels in MS patients.

Main Methods:

• Sera from multiple sclerosis patients and normal individuals were collected.
• Serum levels of intestinal alkaline phosphatase (Pp2) were measured.
• Specimens were matched for ABO and secretor frequencies between patient and control groups.

Main Results:

• A significant deficit of serum intestinal alkaline phosphatase (Pp2) was observed in multiple sclerosis patients compared to normal sera.
• This deficit was not attributable to variations in ABO or secretor frequencies.
• The reduction in Pp2 levels was particularly noticeable in multiple sclerosis patients with blood group O.

Conclusions:

• Patients with multiple sclerosis exhibit a real deficit in serum intestinal alkaline phosphatase (Pp2).
• This finding suggests a potential biomarker or contributing factor in MS, especially in individuals with blood group O.
• Further research is warranted to elucidate the functional implications of reduced Pp2 in MS pathogenesis.